Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study

Katie Harris, Megumi Oshima, Naveed Sattar, Peter Würtz, Min Jun, Paul Welsh, Pavel Hamet, Stephen Harrap, Neil Poulter, John Chalmers, Mark Woodward, Katie Harris, Megumi Oshima, Naveed Sattar, Peter Würtz, Min Jun, Paul Welsh, Pavel Hamet, Stephen Harrap, Neil Poulter, John Chalmers, Mark Woodward

Abstract

Aims/hypothesis: This biomarker study aimed to quantify the association of essential and other plasma fatty acid biomarkers with macrovascular disease, microvascular disease and death in individuals with type 2 diabetes.

Methods: A case-cohort study (N = 3576), including 654 macrovascular events, 341 microvascular events and 631 deaths during 5 years of (median) follow-up, was undertaken as a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) study (full details of the study design and primary endpoints of the ADVANCE trial and its case-cohort have been published previously). This current study considers new data: fatty acids measured from baseline plasma samples by proton NMR analysis. The fatty acids measured were n-3, docosahexaenoic acid (DHA), n-6, linoleic acid, and polyunsaturated, monounsaturated and saturated fatty acids. HRs were modelled per SD higher (percentage) fatty acid. C statistics and continuous net reclassification improvement were used to test the added value of fatty acids compared with traditional cardiovascular risk factors.

Results: After adjustment for traditional cardiovascular risk factors, an inverse association was observed for n-3 fatty acids and DHA with the risk of macrovascular events (HR [95% CI]: 0.87 [0.80, 0.95] and 0.88 [0.81, 0.96], respectively, per 1 SD higher percentage), and for n-3 fatty acids with the risk of death (HR 0.91 [95% CI 0.84, 0.99] per 1 SD higher percentage). Such associations were also evident when investigating absolute levels of fatty acids. There were no statistically significant associations between any fatty acids and microvascular disease after adjustment. However, there was limited improvement in the predictive ability of models when any fatty acid was added.

Conclusions/interpretation: Plasma n-3 fatty acids and DHA were found to be inversely associated with macrovascular disease, while n-3 fatty acids were also inversely associated with death. These results support the cardioprotective effects of n-3 fatty acids and DHA and further merit testing the role of high-dose supplementation with n-3 fatty acids in individuals with type 2 diabetes.

Trial registration: ClinicalTrials.gov NCT00145925. Graphical abstract.

Keywords: Diabetes complications; Docosahexaenoic acid (DHA); Plasma Fatty acids; Type 2 diabetes; n-3 fatty acids.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7351876/bin/125_2020_5162_Figa_HTML.jpg
Graphical abstract
Fig. 1
Fig. 1
Flow diagram for design of ADVANCE case-cohort study of fatty acid biomarkers for macrovascular events, microvascular events and death. aMacrovascular events, microvascular events and death are not mutually exclusive
Fig. 2
Fig. 2
Adjusted HRs for macrovascular events, microvascular events and death associated with fatty acid levels (per 1 SD increase in percentage of total fatty acids), using multiple-adjusted models. Models were adjusted for age, sex, region, randomised treatment, history of macrovascular disease, duration of diabetes, current smoking status, systolic BP, BMI, urinary albumin/creatinine ratio, eGFR, HbA1c, HDL-cholesterol, triacylglycerols, and use of aspirin or other antiplatelet agents, statins or other lipid-lowering agents, β-blockers, and ACE inhibitors or angiotensin receptor blockers
Fig. 3
Fig. 3
Adjusted HRs for individual components of macrovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) associated with n-3 fatty acid and DHA levels (per 1 SD increase in percentage of total fatty acids,) using multiple-adjusted models. Models were adjusted for age, sex, region, randomised treatment, history of macrovascular disease, duration of diabetes, current smoking status, systolic BP, BMI, urinary albumin/creatinine ratio, eGFR, Hb1c, HDL-cholesterol, triacylglycerols, and use of aspirin or other antiplatelet agents, statins or other lipid-lowering agents, β-blockers, ACE inhibitors or angiotensin receptor blockers

References

    1. International Diabetes Federation . IDF diabetes atlas. Brussels, Belgium: International Diabetes Federation; 2017.
    1. Ma J, Folsom AR, Shahar E, Eckfeldt JH (1995) Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) study investigators. Am J Clin Nut 62(3):564–571. 10.1093/ajcn/62.3.564
    1. Hafizi Abu Bakar M, Kian Kai C, Wan Hassan WN, Sarmidi MR, Yaakob H, Zaman Huri H (2015) Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: the roles of long chain fatty acids. Diabetes Meta Res Rev 31(5):453–475. 10.1002/dmrr.2601
    1. Abdelhamid AS, Brown TJ, Brainard JS et al (2018) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev (7):CD003177. 10.1002/14651858.CD003177.pub3
    1. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B (2012) Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Cir. Cardiovas Qual Outcomes 5(6):808–818. 10.1161/CIRCOUTCOMES.112.966168
    1. Hu Y, Hu FB, Manson JE (2019) Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc 8(19):e013543. 10.1161/JAHA.119.013543
    1. Bhatt DL, Steg PG, Miller M et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Eng J of Med 380(1):11–22. 10.1056/NEJMoa1812792
    1. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673–e691. doi: 10.1161/CIR.0000000000000709.
    1. Del Gobbo LC, Imamura F, Aslibekyan S et al (2016) ω-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med 176(8):1155–1166. 10.1001/jamainternmed.2016.2925
    1. de Oliveira Otto MC, Wu JH, Baylin A et al (2013) Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. J A Heart Assoc 2(6):e000506. 10.1161/JAHA.113.000506
    1. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840. doi: 10.1016/S0140-6736(07)61303-8.
    1. Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J of Med 358(24):2560–2572. 10.1056/NEJMoa0802987
    1. Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37(1):295–303. doi: 10.2337/dc13-1165.
    1. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M (2017) Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. A J Epidemiol 186(9):1084–1096. 10.1093/aje/kwx016
    1. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009;134(9):1781–1785. doi: 10.1039/b910205a.
    1. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M (2015) Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Cir Cardiovasc Genet 8(1):192–206. 10.1161/CIRCGENETICS.114.000216
    1. Harrell FEJ. Regression modeling strategies. New York: Springer; 2001.
    1. Prentice RL, Marek P. A qualitative discrepancy between censored data rank tests. Biometrics. 1979;35(4):861–867. doi: 10.2307/2530120.
    1. Kim Y, Kong L (2015) Estimation of C-index for Cox proportional hazards model with censored biomarker covariate subject to limits of detection. J Biopharm Stat 25(3):459–473. 10.1080/10543406.2014.920859
    1. Zheng Y, Parast L, Cai T, Brown M (2013) Evaluating incremental values from new predictors with net reclassification improvement in survival analysis. Lifetime Data Anal 19(3):350–370. 10.1007/s10985-012-9239-z
    1. Sun Q, Ma J, Campos H et al (2008) Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. A Am J Clin Nutrition 88(1):216–223. 10.1093/ajcn/88.1.216
    1. Mozaffarian D, Lemaitre RN, King IB et al (2013) Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med 158(7):515–525. 10.7326/0003-4819-158-7-201304020-00003
    1. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS (2003) n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 77(2):319–325. 10.1093/ajcn/77.2.319
    1. Matthan NR, Ooi EM, Van Horn L, Neuhouser ML, Woodman R, Lichtenstein AH (2014) Plasma phospholipid fatty acid biomarkers of dietary fat quality and endogenous metabolism predict coronary heart disease risk: a nested case–control study within the Women's Health Initiative observational study. J Am Heart Assoc 3(4). 10.1161/JAHA.113.000764
    1. Albert CM, Campos H, Stampfer MJ et al (2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. Eng J Med 346(15):1113–1118. 10.1056/NEJMoa012918
    1. Simon JA, Hodgkins ML, Browner WS, Neuhaus JM, Bernert JT Jr, Hulley SB (1995) Serum fatty acids and the risk of coronary heart disease. Am J Epidemiol 142(5):469–476. 10.1093/oxfordjournals.aje.a117662
    1. Aung T, Halsey J, Kromhout D et al (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 3(3):225–234. 10.1001/jamacardio.2017.5205
    1. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15):e867–e884. doi: 10.1161/CIR.0000000000000482.
    1. Elagizi A, Lavie CJ, Marshall K, DiNicolantonio JJ, O'Keefe JH, Milani RV (2018) Omega-3 polyunsaturated fatty acids and cardiovascular health: a comprehensive review. Progress in Cardiovasc Dis 61(1):76–85. 10.1016/j.pcad.2018.03.006
    1. O'Keefe EL, Harris WS, DiNicolantonio JJ et al (2019) Sea change for marine omega-3s: randomized trials show fish oil reduces cardiovascular events. Mayo Clin Proc 94(12):2524–2533. 10.1016/j.mayocp.2019.04.027
    1. The ASCEND Study Collaborative Group (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. New Eng J Med 379(16):1540–1550. 10.1056/NEJMoa1804989
    1. Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis. 2009;206(2):535–539. doi: 10.1016/j.atherosclerosis.2009.03.029.
    1. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–1230. doi: 10.1016/S0140-6736(08)61239-8.
    1. Kromhout D, Geleijnse JM, de Goede J, et al. N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34(12):2515–2520. doi: 10.2337/dc11-0896.
    1. Tajuddin N, Shaikh A, Hassan A. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:109–118. doi: 10.2147/DMSO.S97036.
    1. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia. 2007;50(8):1593–1602. doi: 10.1007/s00125-007-0695-z.
    1. De Luis DA, Conde R, Aller R et al (2009) Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. Eur Rev for Med Pharmacol Sci 13(1):51–55
    1. Hendrich S (2010) (n-3) Fatty acids: clinical trials in people with type 2 diabetes. Adv Nutr 1(1):3–7. 10.3945/an.110.1003
    1. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296(15):1885–1899. doi: 10.1001/jama.296.15.1885.
    1. Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58(20):2047–2067. 10.1016/j.jacc.2011.06.063
    1. Rimm EB, Appel LJ, Chiuve SE, et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2018;138(1):e35–e47. doi: 10.1161/CIR.0000000000000574.
    1. Lelli D, Antonelli Incalzi R, Ferrucci L, Bandinelli S, Pedone C (2020) Association between PUFA intake and serum concentration and mortality in older adults: a cohort study. Clin Nutr 39(2):510–515. 10.1016/j.clnu.2019.02.030
    1. Wang L, Folsom AR, Eckfeldt JH (2003) Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Nutr, Metab Cardiovasc Dis 13(5):256–266. 10.1016/S0939-4753(03)80029-7
    1. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality. Circulation. 2019;139(21):2422–2436. doi: 10.1161/circulationaha.118.038908.
    1. Clarke R, Shipley M, Armitage J, Collins R, Harris W (2009) Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Br J Nutr 102(2):279–284. 10.1017/S0007114508143562
    1. Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131(9):774–785. doi: 10.1161/CIRCULATIONAHA.114.013116.
    1. Lauretani F, Semba RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal function. Clinical Chemistry. 2008;54(3):475–481. doi: 10.1373/clinchem.2007.095521.
    1. Block R, Kakinami L, Liebman S, Shearer GC, Kramer H, Tsai M (2012) Cis-vaccenic acid and the Framingham risk score predict chronic kidney disease: the Multi-ethnic Study of Atherosclerosis (MESA). Prostaglandins Leukot Essent Fatty Acids 86(4–5):175–182. 10.1016/j.plefa.2012.02.009
    1. Anton G, Wilson R, Yu ZH, et al. Pre-analytical sample quality: metabolite ratios as an intrinsic marker for prolonged room temperature exposure of serum samples. PLoS One. 2015;10(3):e0121495. doi: 10.1371/journal.pone.0121495.
    1. Schutte BAM, van den Akker EB, Deelen J, et al. The effect of standardized food intake on the association between BMI and 1H-NMR metabolites. Scientific Reports. 2016;6(1):38980. doi: 10.1038/srep38980.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe